innoscripta SE, a provider of the Clusterix software platform for managing research and development activities, announced its financial results for the first half of 2026, showing significant growth and successful international expansion. The company reported a 43% increase in revenue compared to the same period last year, reaching EUR 63.1 million. Adjusted EBIT rose by 49% to EUR 36.4 million, after adjusting for EUR 535 thousand in non-recurring expenses related to corporate restructuring. The adjusted EBIT margin stood at an impressive 57.7%.
The German R&D tax allowance (Forschungszulage) continues to be a key growth driver, leading to a surge in the number of customers to over 2,900 during the first half of the year. This government incentive encourages companies to invest in research and development, and innoscripta's software helps them manage and document their projects to claim the allowance efficiently.
Central to innoscripta's strategy is the enhancement of Clusterix as its core platform infrastructure. The company has invested in automated data validation and higher data quality, which enables faster and more standardized processes. This technological foundation is crucial for scaling the business model internationally, as it allows consistent workflows across different markets and adapts flexibly to various regulatory requirements.
The company has made significant strides in its international expansion, opening its first office in France near Toulouse and already securing customers there. In the UK, innoscripta entered the market with a location in Manchester as of July 1, 2026, and has also begun operations in the United States, a high-growth market, where it has started serving its first clients. Additionally, the company opened a new office in Hamburg, Germany, to strengthen its regional presence.
Management confirms its guidance for the full year 2026, expecting revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of application submissions and approvals. The company will host a virtual earnings call to discuss these results, with details available on its website.
innoscripta's performance underscores the growing importance of digital solutions for managing R&D activities, especially in light of government incentives like the German research allowance. The company's ability to enter new markets efficiently, thanks to the flexibility of its platform, positions it well for continued growth.
